New drug trial aims to protect muscle in rare genetic disease
NCT ID NCT07435129
Summary
This study is testing whether an investigational drug called apitegromab can help preserve muscle in adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 60 participants will receive either the drug or a placebo for one year to see if it slows muscle loss. The main goal is to see if the treatment increases lean muscle volume compared to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.